acquired
Stage
1
Investors
About
Okairos AG was a biotechnology company that developed viral-vectored vaccines designed to elicit strong T-cell responses, using adenoviral and modified vaccinia Ankara (MVA) platforms for infectious diseases and immunotherapy.
Explore Okairos AG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.